A comparison of AmBisome® to amphotericin B for treatment of systemic candidiasis in very low birth weight infants

Yonsei Medical Journal

Volumn 48, Issue 4, 2007, Pages 619-626

  Jeon, Ga Won ^a   Koo, Soo Hyun ^a   Lee, Jang Hoon ^b   Hwang, Jong Hee ^c   Kim, Sung Shin ^d   Lee, Eun Kyung ^e   Chang, Wook ^e   Chang, Yun Sil ^a   Park, Won Soon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Inje University   (South Korea)

^d Soonchunhyang University   (South Korea)

^e CHA University   (South Korea)

Author keywords

Candida; Liposomal amphotericin B; Very low birth weight infants

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AMPHOTERICIN B;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANDIDA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; ERADICATION THERAPY; FEMALE; FUNGUS ISOLATION; HUMAN; HYPOKALEMIA; INFANT; INVASIVE CANDIDIASIS; LIVER TOXICITY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; OLIGURIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; VERY LOW BIRTH WEIGHT; CANDIDIASIS; NEWBORN;

AMPHOTERICIN B; CANDIDIASIS; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; MALE;

EID: 34848825584     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2007.48.4.619     Document Type: Article

References (24)

1. Juster-Reicher A, Leibovitz E, Linder N, Amitay M, Flidel-Rimon O, Even-Tov S, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000;28:223-6.
2. Rodriguez D, Almirante B, Park BJ, Cuenca-Estrella M, Planes AM, Sanchez F, et al. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J 2006;25:224-9.
3. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-91.
4. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006;117:1680-7.
5. Adler A, Litmanovitz I, Regev R, Arnon S, Bauer S, Dolfin T. Breakthrough candida infection in a preterm infant with congenital cutaneous Candida albicans infection. Am J Perinatol 2005;22:169-72.
6. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J. 1998;17:504-8.
7. Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006;117:84-92.
8. Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol 2004;26:421-6.
9. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002;49 Suppl 1:37-41.
10. Cuzzolin L, Fanos V, Pirma B, di Marzio M, Perin M, Tramontozzi P, et al. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 2006;21:931-8.
11. Bueva A, Guignard JP. Renal function in preterm neonates. Pediatr Res 1994;36:572-7.
12. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000;30:653-7.
13. Cetin H, Yalaz M, Akisu M, Hilmioglu S, Metin D, Kultursay N. The efficacy of two different lipid-based amphotericin B in neonatal Candida septicemia. Pediatr Int 2005;47:676-80.
14. Charles A. Dinarello, Jeffrey A. Gelfand. Fever and Hyperthermia. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw-Hill; 2005. p.104-8.
15. Weitkamp JH, Poets CF, Sievers R, Musswessels E, Groneck P, Thomas P, et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 1998;26:11-5.
16. Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz E. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis 2003;22: 603-7.
17. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and preclinical experience. J Antimicrob Chernother 2002;49 Suppl 1:21-30.
18. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-18.
19. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: therapeutic toxicity. Pediatrics 1984;73:153-7.
20. Scarcella A, Pasquariello MB, Giugliano B, Vendemmia M, de Lucia A. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998;17: 146-8.
21. Bliss JM, Wellington M, Gigliotti F. Antifungal pharmacotherapy for neonatal candidiasis. Semin Perinatol 2003;27:365-74.
22. Olin JL, Spooner LM. Amphotericin B-associated hyperbilirubinemia: case report and review of the literature. Pharmacotherapy 2006;26:1011-7.
23. Mohan UR, Bush A. Amphotericin B-induced hepatorenal failure in cystic fibrosis. Pediatr Pulmonol 2002,33:497-500.
24. Linder N, Klinger G, Shalit I, Levy I, Ashkenazi S, Haski G, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother 2003;52:663-7.